Cargando…

Virology analysis in HCV genotype 1-infected patients treated with the combination of simeprevir and TMC647055/ritonavir, with and without ribavirin, and JNJ-56914845

BACKGROUND: In study TMC647055HPC2001, a 3-direct-acting-antiviral (DAA) regimen combining NS3/4A protease inhibitor simeprevir (SMV), non-nucleoside NS5B inhibitor TMC647055/ritonavir (RTV) and NS5A inhibitor JNJ-56914845 resulted in high sustained virologic response 12 weeks after actual end of tr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vijgen, Leen, Thys, Kim, Vandebosch, An, Van Remoortere, Pieter, Verloes, René, De Meyer, Sandra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5452362/ https://www.ncbi.nlm.nih.gov/pubmed/28569206 http://dx.doi.org/10.1186/s12985-017-0760-2

Ejemplares similares

Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infection
por: Bourgeois, Stefan, et al.
Publicado: (2017)

Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study
por: Hayashi, Norio, et al.
Publicado: (2013)

Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin
por: Feld, Jordan J., et al.
Publicado: (2018)

Simeprevir, daclatasvir, and sofosbuvir for hepatitis C virus‐infected patients: Long‐term follow‐up results from the open‐label, Phase II IMPACT study
por: Lawitz, Eric, et al.
Publicado: (2020)

JNJ-4178 (adafosbuvir, odalasvir, and simeprevir) in Japanese patients with chronic hepatitis C virus genotype 1 or 2 infection with or without compensated cirrhosis: the Phase IIa OMEGA-3 study
por: Takehara, Tetsuo, et al.
Publicado: (2020)

Predictive factors for 24 weeks sustained virologic response (SVR24) and viral relapse in patients treated with simeprevir plus peginterferon and ribavirin
por: Nakayama, Masahiko, et al.
Publicado: (2015)

Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir and With or Without Ribavirin for Adolescents With HCV Genotype 1 or 4
por: Leung, Daniel H., et al.
Publicado: (2018)

Ombitasvir/paritaprevir/ritonavir and dasabuvir±ribavirin for chronic HCV infection in US veterans with psychiatric disorders
por: Fuchs, Michael, et al.
Publicado: (2020)

Real-world experience with ombitasvir/paritaprevir boosted with ritonavir and possibly combined with dasabuvir and ribavirin in HCV infection
por: Pogorzelska, Joanna, et al.
Publicado: (2016)

Pre-existence and Persistence of Resistant Minority Hepatitis C Virus Variants in Genotype 1-Infected Patients Treated With Simeprevir/Peginterferon/Ribavirin
por: Fevery, Bart, et al.
Publicado: (2016)

Sofosbuvir in combination with ribavirin or simeprevir: real-life study of patients with hepatitis C genotype 4
por: Abdel-Moneim, Adel, et al.
Publicado: (2019)

Evaluation of the Pharmacokinetics and Renal Excretion of Simeprevir in Subjects with Renal Impairment
por: Ouwerkerk-Mahadevan, Sivi, et al.
Publicado: (2015)

Sustained virological response in HIV/HCV co-infected patients without rapid virological response (RVR) on peginterferon-ribavirin therapy
por: Labarga, P, et al.
Publicado: (2010)

An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1)
por: Asselah, Tarik, et al.
Publicado: (2016)

Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic Response
por: Asselah, Tarik, et al.
Publicado: (2017)

The impact of ribavirin on real-world adherence rates in hepatitis C patients treated with sofosbuvir plus simeprevir
por: Walker, David R, et al.
Publicado: (2015)

On-Treatment Elevation in Hepatic Transaminases during HCV Treatment with Ombitasvir, Paritaprevir, Dasabuvir, Ritonavir, and Ribavirin: A Case Series
por: Bean, Madelyne, et al.
Publicado: (2016)

Peripheral blood correlates of virologic relapse after Sofosbuvir and Ribavirin treatment of Genotype-1 HCV infection
por: Orr, Cody, et al.
Publicado: (2020)

Ribavirin Concentrations Do Not Predict Sustained Virological Response in HIV/HCV-Coinfected Patients Treated with Ribavirin and Pegylated Interferon in the Swiss HIV Cohort Study
por: Kovari, Helen, et al.
Publicado: (2015)

Ombitasvir/paritaprevir/ritonavir + dasabuvir + ribavirin in HCV genotype 1 infected patients who failed previous protease inhibitor therapy
por: Hunyady, Béla, et al.
Publicado: (2018)

Simeprevir with peginterferon/ribavirin for patients with hepatitis C virus genotype 1: high frequency of viral relapse in elderly patients
por: Watanabe, Takao, et al.
Publicado: (2016)

Lower response to simeprevir and sofosbuvir in HCV genotype 1 in routine practice compared with clinical trials
por: Yee, Brittany E, et al.
Publicado: (2016)

Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents
por: Shiffman, Mitchell L, et al.
Publicado: (2016)

Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir ± ribavirin in HIV/HCV co-infected patients
por: Taramasso, Lucia, et al.
Publicado: (2018)

Ombitasvir/paritaprevir/ritonavir plus ribavirin for 24 weeks in patients with HCV GT4 and compensated cirrhosis (AGATE‐I Part II)
por: Asselah, Tarik, et al.
Publicado: (2019)

ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection
por: Asselah, Tarik, et al.
Publicado: (2015)

Peginterferon plus ribavirin and sustained virological response rate in HCV-related advanced fibrosis: a real life study
por: Silva, Giovanni Faria, et al.
Publicado: (2013)

Successful Treatment of Hepatitis C with Simeprevir, Sofosbuvir, and Ribavirin in an HIV Coinfected Liver Transplant Patient with Advanced Chronic Kidney Disease
por: Maruyama, Anna, et al.
Publicado: (2016)

Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor simeprevir and frequently used concomitant medications
por: Marra, Fiona, et al.
Publicado: (2018)

Combination Therapy of Simeprevir and Sofosbuvir in Recurrent HCV Genotype 4 After Liver Retransplantation: Case Report
por: Obed, Aiman, et al.
Publicado: (2016)

Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir With or Without Ribavirin in Patients With Kidney Disease
por: Bernstein, David E., et al.
Publicado: (2018)

Favorable Outcomes of Chinese HCV-Related Cirrhotic Patients with Sustained Virological Response after Pegylated Interferon Plus Ribavirin Treatment
por: Zhang, Geng-lin, et al.
Publicado: (2017)

Sustained virological response in patients with HCV treated with daclatasvir plus sofosbuvir, with or without ribavirin: a large, field-practice study
por: Sacco, Rodolfo, et al.
Publicado: (2020)

Efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with ribavirin for the treatment of HCV genotype 1b compensated cirrhosis in patients aged 70 years or older
por: Trifan, Anca, et al.
Publicado: (2017)

Sustained Virological Response after 8-Week Treatment of Simeprevir with Peginterferon α-2a plus Ribavirin in a Japanese Female with Hepatitis C Virus Genotype 1b and IL28B Minor Genotype
por: Kanda, Tatsuo, et al.
Publicado: (2015)

Circulating sCD14 Is Associated with Virological Response to Pegylated-Interferon-Alpha/Ribavirin Treatment in HIV/HCV Co-Infected Patients
por: Marchetti, Giulia, et al.
Publicado: (2012)

The influence of anti-HBc status on the sustained virological response rate in HCV-infected patients treated with pegylated interferon alfa 2 and ribavirin
por: Szymanek-Pasternak, Anna, et al.
Publicado: (2016)

Ombitasvir/paritaprevir/ritonavir + dasabuvir +/- ribavirin in real world hepatitis C patients
por: Loo, Nicole, et al.
Publicado: (2019)

European vs. Egyptian HCV-4 Patients with Elevated Baseline HCV RNA, Treated with PEG-IFN-α2a and Ribavirin: The Role of Rapid and Early Virologic Response
por: Dimitroulopoulos, Dimitrios, et al.
Publicado: (2010)

Sofosbuvir in Combination with Simeprevir +/- Ribavirin in Genotype 4 Hepatitis C Patients with Advanced Fibrosis or Cirrhosis: A Real-World Experience from Belgium
por: Degré, Delphine, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_u2ln5v4t8amtens6phgp3161t1